APRIL Antibody (Sacha-1): sc-57035

APRIL Antibody (Sacha-1) is a rat monoclonal IgG2a antibody that detects APRIL in mouse, rat, and human samples through immunofluorescence (IF) and flow cytometry (FCM) applications. APRIL, also known as TNFSF13, is a Type II membrane protein that plays a pivotal role in immune regulation, particularly in infections, inflammation, autoimmune diseases, and tissue homeostasis. APRIL is predominantly expressed in transformed cell lines and various tumor tissues, including those from the colon, thyroid, and lymphoid systems, highlighting APRIL′s significance in tumor biology and immune responses. The structure of APRIL is particularly noteworthy; APRIL′s C-terminal extracellular domain exhibits a jelly roll topography, which is crucial for ligand trimerization. This structural feature facilitates APRIL′s binding to receptors, leading to oligomerization that triggers downstream signaling pathways essential for cellular communication and function. The formation of the receptor binding site at the junction of neighboring subunits creates a multivalent ligand, enhancing APRIL′s efficacy in mediating biological effects. With unique properties and critical functions, anti-APRIL antibody (Sacha-1) serves as an invaluable tool for researchers investigating APRIL′s complex roles in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

APRIL Antibody (Sacha-1) References:

1. A proliferation inducing ligand (APRIL) promotes IL-10 production and regulatory functions of human B cells.  |  Hua, C., et al. 2016. J Autoimmun. 73: 64-72. PMID: 27372914
2. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.  |  Samy, E., et al. 2017. Int Rev Immunol. 36: 3-19. PMID: 28215100
3. The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting.  |  Baert, L., et al. 2018. J Autoimmun. 95: 179-190. PMID: 30385081
4. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy.  |  Myette, JR., et al. 2019. Kidney Int. 96: 104-116. PMID: 31027890
5. The roles of B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) in allergic asthma.  |  Alturaiki, W. 2020. Immunol Lett. 225: 25-30. PMID: 32522667
6. Plasma Levels of the Cytokines B Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) in Schizophrenia, Bipolar, and Major Depressive Disorder: A Cross Sectional, Multisite Study.  |  Engh, JA., et al. 2022. Schizophr Bull. 48: 37-46. PMID: 34499169
7. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.  |  Shi, F., et al. 2021. Immunopharmacol Immunotoxicol. 43: 666-673. PMID: 34519594
8. The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy.  |  Yeo, SC. and Barratt, J. 2023. Clin Kidney J. 16: ii9-ii18. PMID: 38053976
9. Targeting APRIL in the treatment of glomerular diseases.  |  Cheung, CK., et al. 2024. Kidney Int. 106: 806-818. PMID: 39182759
10. The inflammatory APRIL (a proliferation-inducing ligand) antagonizes chondroitin sulphate proteoglycans to promote axonal growth and myelination.  |  Ahmed, MC., et al. 2025. Brain Commun. 7: fcae473. PMID: 39926615

The preferred APRIL antibody is APRIL Antibody (F-5): sc-374673.